valproic acid has been researched along with Cerebral Hemorrhage in 12 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Cerebral Hemorrhage: Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of our study was to assess the occurrence of seizures and neurologic outcome in SICH patients who were treated with valproic acid or a placebo for a period of one month and follow-up of one year in a hospital inpatient neurologic department and ambulatory clinic settings." | 5.15 | Are post intracerebral hemorrhage seizures prevented by anti-epileptic treatment? ( Boaz, M; Dabby, R; Gilad, R; Lampl, Y; Sadeh, M, 2011) |
| " Following surgery, he routinely received valproic acid (VPA) to prevent seizures." | 4.89 | Valproic acid-associated low fibrinogen and delayed intracranial hemorrhage: case report and mini literature review. ( Chen, HF; Cui, QY; Jin, LJ; Li, ZY; Luo, ZY; Qin, LM; Ren, YY; Shen, HS; Tang, JQ; Wang, J; Wang, KY; Wang, ZY; Wu, TQ; Xu, LP; Yu, ZQ; Zhu, JJ, 2013) |
| "Seizures after intracerebral hemorrhage are a common complication and may adversely affect neurological outcome." | 2.79 | Protocol for seizure prophylaxis following intracerebral hemorrhage study (SPICH): a randomized, double-blind, placebo-controlled trial of short-term sodium valproate prophylaxis in patients with acute spontaneous supratentorial intracerebral hemorrhage. ( Cao, X; Fang, Y; Fu, M; Hu, X; Li, H; Li, X; Lin, S; Liu, M; Liu, W; You, C; Zhang, H, 2014) |
| "Seizures were classified as early seizure (first seizure within 1 week of ICH), delayed seizure (first seizure after 1 week), and late seizure (any seizure after 1 week)." | 1.62 | Discontinuation of preventive antiepileptic drugs in patients with intracerebral hemorrhage. ( Ong, CT; Wong, YS; Wu, CS, 2021) |
| "After intracerebral hemorrhage (ICH), mechanical compression by hematoma, neuroinflammation, oxidative stress, and cytotoxicity of hematoma lysates caused the destruction of the blood brain barrier (BBB)." | 1.56 | Valproate Sodium Protects Blood Brain Barrier Integrity in Intracerebral Hemorrhage Mice. ( Guo, Z; Hou, Y; Jiang, J; Song, Y; Zhao, L; Zhao, W, 2020) |
| " All these patients were receiving the usual dosage (1000 to 1500 mg per day) of Valproic acid (VPA)." | 1.29 | Impairment of consciousness induced by valproate treatment following neurosurgical operation. ( Baulac, M; de Billy, A; Durand, G; Landau, J; Philippon, J, 1993) |
| "Cerebral cavernous angioma (cavernoma) has previously been treated by resection for all presentations when surgically resectable." | 1.28 | Cerebral cavernous angioma: a potentially benign condition? Successful treatment in 16 cases. ( Churchyard, A; Grainger, K; Khangure, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, W | 1 |
| Zhao, L | 1 |
| Guo, Z | 1 |
| Hou, Y | 1 |
| Jiang, J | 1 |
| Song, Y | 1 |
| Wong, YS | 1 |
| Wu, CS | 1 |
| Ong, CT | 1 |
| Chen, HF | 1 |
| Xu, LP | 1 |
| Luo, ZY | 1 |
| Yu, ZQ | 1 |
| Li, ZY | 1 |
| Cui, QY | 1 |
| Qin, LM | 1 |
| Ren, YY | 1 |
| Shen, HS | 1 |
| Tang, JQ | 1 |
| Jin, LJ | 1 |
| Zhu, JJ | 1 |
| Wang, J | 1 |
| Wang, KY | 1 |
| Wu, TQ | 1 |
| Wang, ZY | 1 |
| Hu, X | 1 |
| Fang, Y | 1 |
| Li, H | 1 |
| Liu, W | 1 |
| Lin, S | 1 |
| Fu, M | 1 |
| Li, X | 1 |
| Cao, X | 1 |
| Zhang, H | 1 |
| You, C | 1 |
| Liu, M | 1 |
| Labro, H | 1 |
| Al-Kadhimi, Z | 1 |
| Djmil, M | 1 |
| Oghlakian, R | 1 |
| Alshekhlee, A | 1 |
| Gilad, R | 1 |
| Boaz, M | 1 |
| Dabby, R | 1 |
| Sadeh, M | 1 |
| Lampl, Y | 1 |
| Sakuta, R | 1 |
| Tomita, Y | 1 |
| Ohashi, M | 1 |
| Nagai, T | 1 |
| Murakami, N | 1 |
| Sinn, DI | 1 |
| Kim, SJ | 1 |
| Chu, K | 1 |
| Jung, KH | 1 |
| Lee, ST | 1 |
| Song, EC | 1 |
| Kim, JM | 1 |
| Park, DK | 1 |
| Kun Lee, S | 1 |
| Kim, M | 1 |
| Roh, JK | 1 |
| Landau, J | 1 |
| Baulac, M | 1 |
| Durand, G | 1 |
| de Billy, A | 1 |
| Philippon, J | 1 |
| Riol Diego, M | 1 |
| Narbona García, J | 1 |
| Churchyard, A | 1 |
| Khangure, M | 1 |
| Grainger, K | 1 |
| Lefkowitz, D | 1 |
| Harpold, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain[NCT01928849] | Phase 2 | 128 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The S-LANSS is a self-reported version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. It aims to differentiate neuropathic pain from somatic or nociceptive pain. We will analyze the change in numeric average pain score during the past week (range from 0-10) from baseline. Higher scores indicate greater pain. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) |
|---|---|
| Cherry Syrup | -2 |
| Valproic Acid | -2 |
The primary endpoint is the incidence of chronic pain after surgery. The study team will use the average pain score over the past week as noted on the Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) for the assessment of pain, and define chronic pain as a score greater than or equal to 3. (NCT01928849)
Timeframe: 3 months or time of final adjudication assessment, up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cherry Syrup | 37 |
| Valproic Acid | 36 |
The BPI short form is a multidimensional patient-completed measure that assesses the sensory component of pain intensity. We will analyze the change in average pain score question (ranges 0-10) and the sum of the 7 interference questions (total range 0-70) from baseline. Higher score indicates greater pain and interference. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) | |
|---|---|---|
| BPI Average Pain Score | BPI interference question sum | |
| Cherry Syrup | -2 | -15 |
| Valproic Acid | -1 | -7 |
The DVPRS is a pain assessment tool developed by the military in an effort to improve reliability and interpretability of pain assessment in the military population. It has been found to be an effective and valid tool in this population. We will analyze the change in numeric pain response (range 0-10) and the sum of the four supplemental questions (range 0-40) from baseline. Higher scores indicate greater pain and functional limitations. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) | |
|---|---|---|
| DVPRS numeric pain | DVPRS Supplemental Question Sum | |
| Cherry Syrup | -2 | -9 |
| Valproic Acid | 0 | -4.5 |
The effect of study drug on perioperative analgesic consumption and corresponding analysis of pain/sedation scales. Outcome defined as total opioid consumption (mg) during each 24-hour periods following surgery. (NCT01928849)
Timeframe: Assessments during hospitalization (0-24 hours and 24-48 hours post-surgery)
| Intervention | morphine milligram equivalents (Median) | |
|---|---|---|
| Postoperative hours 0-24 | Postoperative hours 24-48 | |
| Cherry Syrup | 59 | 49 |
| Valproic Acid | 33 | 45 |
The incidence of neuropathic limb or post-amputation pain sub-types as defined by adjudication classification at each assessment time point. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Residual limb pain | Phantom limb | |
| Cherry Syrup | 29 | 22 |
| Valproic Acid | 31 | 26 |
The RASS is a commonly used, valid and reliable assessment tool for use in hospitalized patients. Validity testing reveals good inter-rater reliability among medical, surgical, and intensive care units. We will analyze the numeric score at each assessment (range -5 (unarousable) to 4 (combative)). (NCT01928849)
Timeframe: during hospitalization (0-24 hours and 24-48 hours post-surgery)
| Intervention | score on a scale (Median) | |
|---|---|---|
| Post-op hours 0-24 | Post-op hours 24-48 | |
| Cherry Syrup | 0 | 0 |
| Valproic Acid | 0 | 0 |
1 review available for valproic acid and Cerebral Hemorrhage
| Article | Year |
|---|---|
Valproic acid-associated low fibrinogen and delayed intracranial hemorrhage: case report and mini literature review.
Topics: Adult; Afibrinogenemia; Anticonvulsants; Cerebral Hemorrhage; Humans; Male; Seizures; Time Factors; | 2013 |
2 trials available for valproic acid and Cerebral Hemorrhage
| Article | Year |
|---|---|
Protocol for seizure prophylaxis following intracerebral hemorrhage study (SPICH): a randomized, double-blind, placebo-controlled trial of short-term sodium valproate prophylaxis in patients with acute spontaneous supratentorial intracerebral hemorrhage.
Topics: Acute Disease; Anticonvulsants; Cerebral Hemorrhage; China; Clinical Protocols; Double-Blind Method; | 2014 |
Are post intracerebral hemorrhage seizures prevented by anti-epileptic treatment?
Topics: Aged; Aged, 80 and over; Anticonvulsants; Cerebral Hemorrhage; Female; Follow-Up Studies; Humans; Ma | 2011 |
9 other studies available for valproic acid and Cerebral Hemorrhage
| Article | Year |
|---|---|
Valproate Sodium Protects Blood Brain Barrier Integrity in Intracerebral Hemorrhage Mice.
Topics: Animals; Blood-Brain Barrier; Cerebral Hemorrhage; Disease Models, Animal; Gene Expression Regulatio | 2020 |
Discontinuation of preventive antiepileptic drugs in patients with intracerebral hemorrhage.
Topics: Adult; Aged; Anticonvulsants; Cerebral Hemorrhage; Female; Humans; Male; Middle Aged; Retrospective | 2021 |
Brain amyloidoma with cerebral hemorrhage.
Topics: Amyloidosis; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhag | 2009 |
Idiopathic hypereosinophilic syndrome complicated by central sinovenous thrombosis.
Topics: Anticoagulants; Anticonvulsants; Cerebral Hemorrhage; Child; DNA Mutational Analysis; Epilepsy; Huma | 2007 |
Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation.
Topics: Animals; Apoptosis Regulatory Proteins; Cell Death; Cerebral Hemorrhage; Chemotaxis, Leukocyte; Dise | 2007 |
Impairment of consciousness induced by valproate treatment following neurosurgical operation.
Topics: Adolescent; Adult; Arousal; Brain Neoplasms; Cerebral Hemorrhage; Coma; Consciousness Disorders; Del | 1993 |
[Valproate therapy and cerebral bleeding].
Topics: Cerebral Hemorrhage; Child; Female; Humans; Parietal Lobe; Temporal Lobe; Valproic Acid | 1997 |
Cerebral cavernous angioma: a potentially benign condition? Successful treatment in 16 cases.
Topics: Adolescent; Adult; Angiography; Brain Neoplasms; Carbamazepine; Cerebral Hemorrhage; Child; Epilepsy | 1992 |
Treatment of ocular myoclonus with valproic acid.
Topics: Cerebral Hemorrhage; Eye Movements; Humans; Hypertension; Male; Middle Aged; Myoclonus; Oculomotor M | 1985 |